by April Breyer Menon | Aug 25, 2025
On August 20, 2025, after a bench trial in Case No. 1:22-cv-00035 (D. Del.), Lindis Biotech’s U.S. Patent Nos. 8,709,421 and 10,071,158 (“the Lindis patents”) were found unenforceable due to inequitable conduct for withholding known material references during...
by April Breyer Menon | Aug 22, 2025
On August 18, 2025, Accord and Dong-A ST announced the U.S. launch of Imuldosa® (ustekinumab-srlf), a biosimilar of Janssen / Johnson & Johnson’s Stelara® (ustekinumab). Imuldosa® is approved for all the reference product’s indications, including certain...
by April Breyer Menon | Aug 21, 2025
On August 14, 2025, Genentech filed BPCIA litigation No. 2:25-cv-14648 (D.N.J.) against Shanghai Henlius Biotech (“Henlius”) and Organon alleging infringement of 24 patents by Henlius / Organon’s proposed Perjeta® (pertuzumab) biosimilar HLX11. Henlius and...
by April Breyer Menon | Jul 30, 2025
On July 18, 2025, after a five-day trial, the jury in Allergan v. Revance Case No. 1:21-cv-01411 (D. Del.) entered a verdict finding claim 8 of Allergan’s U.S. Patent No. 7,354,740 (“the ’740 patent”), claim 6 of U.S. Patent No. 11,147,878 (“the ’878 patent”),...
by April Breyer Menon | Jul 30, 2025
On July 24, 2025, the PTO Acting Director Coke Morgan Stewart discretionarily denied Amgen’s IPR2025-00601 and IPR2025-00602 challenging Bristol-Myers Squibb’s (“BMS”) U.S. Patent Nos. 9,856,320 (“the ’320 patent”) and 10,174,113 (“the ’113 patent”)...
